526 Members of Congress Decline to Join Anti-Marijuana Rescheduling Letter to AG Bondi, Just 9 Sign On, Down From 25 in 2024

The signatories include Representatives Pete Sessions (TX), Andy Harris (MD), Robert Aderholt (AL), Paul Gosar (AZ), Chip Roy (TX), Blake Moore (UT), Gary Palmer (AL), David Rouzer (NC), and Mary Miller (IL). No senators signed the letter.

The contrast with last year is stark. In 2024, Smart Approaches to Marijuana (SAM) circulated a similar letter opposing rescheduling that drew the support of 25 lawmakers, including several U.S. senators. This year’s version secured less than half as many backers, with support confined entirely to a small bloc of House Republicans.

The letter, led by Congressman Pete Sessions, warns that rescheduling would provide tax benefits to marijuana businesses and drug cartels, while citing concerns about addiction, mental health impacts, and links to foreign crime organizations. Despite these claims, the limited number of signatures—despite the letter being heavily circulated among lawmakers—underscores the declining influence of marijuana reform opponents in Congress.

With public opinion polls consistently showing majority support for legalization and more states moving to regulate marijuana, the shrinking list of congressional voices against reform highlights how rapidly the political landscape is shifting. Opposition to rescheduling, once much broader, is now increasingly isolated to a small group of lawmakers.

Keep reading

The 10th Circuit Agrees That Prosecuting Cannabis Consumers for Gun Possession May Be Unconstitutional

On a Friday in May 2022, Jared Harrison was on his way to work at an Oklahoma medical marijuana dispensary when a police officer stopped him for running a red light. When Harrison rolled down his window, the officer smelled marijuana. A search of the car discovered a loaded revolver, a pill bottle containing a few partially smoked joints, another joint in a console tray, and a backpack containing marijuana, THC gummies, and two THC vape cartridges.

Because Harrison did not have a state-issued medical marijuana card, he was charged with illegal possession of cannabis under state law, a misdemeanor. But he also faced a felony charge under 18 USC 922(g)(3), the federal law that bars illegal drug users from possessing firearms. That charge, he argued, violated the Second Amendment. A federal judge agreed, ruling in February 2023 that the government had failed to show Harrison’s prosecution was “consistent with this Nation’s historical tradition of firearm regulation”—the constitutional test that the U.S. Supreme Court established in the 2022 case New York State Rifle & Pistol Association v. Bruen.

This week the U.S. Court of Appeals for the 10th Circuit reversed that ruling and remanded the case for further consideration. The 10th Circuit’s decision in United States v. Harrison, because it endorsed U.S. District Judge Patrick Wyrick’s reasoning in nearly all respects, nevertheless represents another in a series of blows to a policy that affects millions of peaceful Americans, depriving them of the constitutional right to armed self-defense for no good reason.

As it has in other Section 922(g)(3) cases, the government argued that cannabis consumers are not part of “the people” whose “right to keep and bear arms” is guaranteed by the Second Amendment because they are not “law-abiding.” Wyrick made short work of that claim, noting that the Supreme Court has said “the people,” as used in the Bill of Rights, “unambiguously refers to all members of the political community, not an unspecified subset.”

The government’s argument amounted to “an outright declaration of the federal government’s belief that it can deprive practically anyone of their Second Amendment right,” Wyrick added. “Who among us, after all, isn’t a ‘lawbreaker’? For sure, there
may well exist some adult[s] who [have] never exceeded the speed limit, changed lanes without signaling, or failed to come to a complete stop at a stop sign, but they are few and far between.”

The three-judge 10th Circuit panel unanimously agreed with Wyrick on this point. “A contrary conclusion would defy law and logic,” Judge Veronica Rossman, a Joe Biden appointee, writes in the majority opinion, which was joined in full by Judge Michael R. Murphy, who was nominated by Bill Clinton, and in part by Judge Paul J. Kelly Jr., who was appointed by George H.W. Bush. “The First and Fourth Amendments also refer to the ‘people,’ and nobody contends only ‘law-abiding citizens’ enjoy the rights protected by these constitutional guarantees….Restricting the Second Amendment to ‘law-abiding’ citizens—as the government urges us to do—would make it harder to administer and would risk turning it into ‘a second-class right.'”

Keep reading

Cannabis Use Linked to Lower Inflammation Among People With HIV or Methamphetamine Disorder

The research, published in the journal Viruses, involved 234 participants, including 86 people with HIV (PWH) and 148 without HIV (PWoH). Participants provided blood and urine samples and completed assessments covering medical, psychiatric, and substance use history. Researchers analyzed markers of immune activity and inflammation, focusing on CXCL10/IP-10, CCL2/MCP-1, ICAM-1, and VCAM-1.

Results showed that participants with HIV had higher levels of CXCL10/IP-10 compared to those without HIV, confirming heightened inflammation in this group. However, cannabis use was independently linked to lower CXCL10/IP-10 levels overall. Among people with lifetime MUD, cannabis use was also tied to reduced levels of CCL2/MCP-1, ICAM-1, and VCAM-1, suggesting cannabis may mitigate immune overactivation in this population. Interestingly, only participants without HIV displayed cannabis-associated reductions in VCAM-1.

The authors conclude that cannabis use is associated with lower concentrations of key immune and inflammatory molecules in individuals with HIV or MUD. They suggest that cannabinoid pathways could offer a promising target for treating complications tied to chronic inflammation.

This study adds to a growing body of evidence that cannabinoids may hold therapeutic value in managing immune dysfunction and inflammation, particularly among populations facing elevated risks due to substance use or chronic conditions.

Keep reading

Federal Appeals Court Says Government Must Prove Marijuana Users ‘Pose A Risk’ Of Danger To Justify Gun Ban

A federal appeals court has ruled that the government must prove that people who use marijuana “pose a risk of future danger” if it wants to justify applying a law banning cannabis consumers from owning firearms.

In its opinion on Tuesday, the U.S. Court of Appeals for the Tenth Circuit sided with a federal district court that dismissed an indictment against Jared Michael Harrison, who was charged in Oklahoma in 2022 after police discovered cannabis and a handgun in his vehicle during a traffic stop.

The case has now been remanded to that lower court, which determined that the current statute banning “unlawful” users of marijuana from possessing firearms, known as 922(g)(3), violates the Second Amendment of the Constitution.

The Justice Department appealed that ruling in 2023, sending it to the Tenth Circuit. That three-judge panel said they “agree with much of the district court’s analysis” of the legal considerations, including its challenge to the federal government’s claims that there is historically analogous precedent substantiating the firearm ban for cannabis consumers.

Keep reading

Anti-Drug, Law Enforcement And Religious Groups Urge Trump To Oppose Marijuana Rescheduling

A coalition of anti-marijuana, law enforcement and religious groups are imploring President Donald Trump to oppose a cannabis rescheduling proposal that he says his administration will decide on within weeks.

Led by Smart Approaches to Marijuana (SAM), the coalition sent a letter to the president on Monday, saying the organizations “strongly urge that you reject reclassifying marijuana as a Schedule III drug” under the Controlled Substances Act (CSA), a move that Trump had endorsed during last year’s campaign.

One signatory of the letter, the Drug Enforcement Association of Federal Narcotics Agents, represents personnel at the Drug Enforcement Administration, the agency that the cannabis reform proposal currently sits before.

“President Trump has an opportunity to make a stand for the safety of children across America by opposing the flawed proposal to reschedule marijuana,” SAM President Kevin Sabet said in a press release. “Marijuana has not been approved for any medical use by the FDA, nor has any raw plant. And it likely never will. It is an addictive drug with a high risk of abuse. That’s why it sat in Schedule I for decades and why it must stay there.”

Cannabis is currently classified as a Schedule I drug, but the Biden administration initiated a scientific review that led it to it to propose moving it to Schedule III. That wouldn’t federally legalize the plant, but it would allow state-licensed marijuana businesses to take federal tax deductions and remove certain barriers to research.

In the letter, the organizations acknowledged that the argument that marijuana shouldn’t be placed in the same schedule as heroin are “politically salient and easy to understand.” However, they said reform advocates “fundamentally misunderstand how drug scheduling works.”

“Contrary to popular belief, drug scheduling is not a harm index,” they said. “Rather, it balances the accepted medical use of a substance with its potential for abuse.”

Keep reading

Oklahoma Bureau of Narcotics shuts down illegal marijuana farms

Oklahoma Bureau of Narcotics agents, with assistance from multiple sheriff’s departments and county commissioners, served search warrants at three marijuana farms in southwestern Oklahoma, seizing over 40,000 plants and more than 1,000 pounds of processed marijuana.

The farms, located near Tipton, Frederick, and Grandfield, were targeted as part of an ongoing investigation into black market marijuana trafficking and fraud. Five people are currently in ICE custody, and investigators expect more arrests.

“We were at the height of this 8,400 grows, seen as the wild west of weed,” said Mark Woodward, with the Oklahoma Bureau of Narcotics. “We’ve really flipped the script, OBN is going to put your business under a microscope, if you’re a criminal you’re going to go to fail.”

Keep reading

Scientists Find First Evidence of Rare Compounds in Cannabis Leaves

Scientists in South Africa say they have found the first evidence of a rare class of phenolics, called ‘flavoalkaloids’, in leaves from the cannabis plant.

Phenolic compounds, especially flavonoids, are well-known and sought after in the pharmaceutical industry because of their antioxidant, anti-inflammatory, and anti-carcinogenic properties.

Researchers from Stellenbosch University have identified 79 phenolic compounds in three strains of cannabis grown commercially in South Africa, of which 25 were reported in the plant for the first time.

Sixteen of these compounds were tentatively identified as ‘flavoalkaloids’, and were mainly found in the leaves of only one of the strains. The findings are published in the Journal of Chromatography A,

First author, Dr Magriet Muller, an analytical chemist in the LC-MS laboratory of the Central Analytical Facility (CAF) at Stellenbosch University, says the analysis of plant phenolics is challenging due to their low concentration and extreme structural diversity.

“Most plants contain highly complex mixtures of phenolic compounds, and while flavonoids occur widely in the plant kingdom, the flavoalkaloids are very rare in nature,” she explains.

“We know that Cannabis is extremely complex – it contains more than 750 metabolites – but we did not expect such high variation in phenolic profiles between only three strains, nor to detect so many compounds for the first time in the species. Especially the first evidence of flavoalkaloids in Cannabis was very exciting.”

Keep reading

Cannabis Seed Oil Has ‘Superior Effectiveness’ In Healing Wounds Compared To Conventional Antibiotics, Study Shows

Cannabis seed oil can help accelerate healing of skin wounds—a promising development that authors say indicates that “hemp seed oil may serve as a promising natural and cost-effective adjunct for wound management”—according to a new study of mice.

The report, published in the journal Narra J, compared wounds treated with hempseed oil against those treated with the conventional antibiotic chloramphenicol. Another group of mice was given only a mild saline solution.

“The findings of the present study highlighted the efficacy of hemp oil in accelerating wound healing processes, particularly wound size reduction, epithelialization, granulation tissue formation, and vascularization,” authors wrote, “with results indicating superior effect compared to chloramphenicol ointment.”

The four-person research team, from Universitas Syiah Kuala in Indonesia, noted that there appeared to be specific portions of the healing process in which hemp oil outperformed treatment with chloramphenicol. During other time frames, however, it seemed “comparable” to the antibiotic.

“Hemp seed oil demonstrated superior effectiveness in accelerating wound size reduction compared to chloramphenicol ointment during days 14 and 21,” the paper says, “indicating its potential as a supportive therapy for prolonged wound healing phases. While both treatments improved epithelialization, the significant effect observed on day 14 in the present study suggested that hemp seed oil may provide particular benefits during this critical stage of wound healing, potentially accelerating the transition to tissue remodeling.”

In terms of tissue formation, “hemp seed oil treatment significantly accelerated granulation tissue formation during wound healing, particularly on day 14, where it outperformed chloramphenicol,” authors wrote. “However, its effect on day 21 was comparable to chloramphenicol.”

Keep reading

The Top 200 Cannabis-Related Studies Published in 2025

Hundreds of peer-reviewed studies on marijuana and its components have been published in the first seven months of 2025, marking a surge in new research. In this article, we break down the 200 most important of these studies.

These studies cover a wide spectrum of conditions, from autoimmune disorders and mental health issues to gastrointestinal diseases and metabolic dysfunction. In addition, researchers are increasingly turning their attention to cannabinoids beyond THC and CBD, such as CBG, THCV, and CBC. Many studies also focus on novel delivery systems—like oral dissolvable films, skin patches, and advanced emulsions—while investigating how marijuana may affect pain regulation, sleep quality, immune response, and emotional health.

What follows is a detailed roundup of more than 200 marijuana-related studies released so far this year.

Keep reading

Marijuana prohibition has been a fraud

Since its inception, efforts to criminalize marijuana and to stigmatize those who consume it have been based upon hyperbole, stereotypes and outright lies.

The initial push for cannabis criminalization, which began in earnest more than a century ago, had little to do with preserving public health or safety. Instead, the move to prosecute cannabis users was based primarily on sensationalism and xenophobia.

For instance, a July 6, 1927, story in the New York Times, headlined “Mexican Family Goes Insane,” farcically claimed: “A widow and her four children have been driven insane by eating the marihuana plant, according to doctors, who say there is no hope of saving the children’s lives and that the mother will be insane for the rest of her life.”

An academic paper titled “Marijuana,” published in 1933 in The Journal of Law and Criminology, similarly made over-the-top allegations about marijuana’s supposed dangers. The authors wrote, “The inevitable result is insanity, which those familiar with it describe as absolutely incurable, and, without exception ending in death.”

By 1937, Harry J. Anslinger — America’s first “Drug Czar” — had successfully lobbied Congress to ban cannabis nationwide. He did so through the continuous use of racist rhetoric. “There are 100,000 total marijuana smokers in the U.S., and most are Negroes, Hispanics, Filipinos and entertainers. Their Satanic music, jazz and swing, result from marijuana use,” he asserted. “This marijuana causes white women to seek sexual relations with Negroes, entertainers and any others.”

Fast-forward to 1971. That’s when the Richard Nixon administration declared drug abuse to be “public enemy number one.” The lynchpin of this campaign was marijuana, which Congress had just classified as a Schedule I controlled substance — the strictest federal category available. Yet, privately, Nixon acknowledged that he did not think cannabis was “particularly dangerous,” and he lamented the “ridiculous” penalties faced by those arrested for possessing it.

Nonetheless, he and those in his administration publicly doubled down on the supposed marijuana threat for reasons that were almost entirely political. As his domestic policy chief, John Ehrlichman, later acknowledged, “We couldn’t make it illegal to be either against the (Vietnam) war or Black,” but we could get “the public to associate the hippies with marijuana and Blacks with heroin.”

By “criminalizing both heavily,” Ehrlichman explained, “we could disrupt those communities. We could arrest their leaders, raid their homes, break up their meetings, and vilify them night after night on the evening news.”

“Did we know we were lying about the drugs?” he asked. “Of course we did.”

Now, 50-plus years later, marijuana remains categorized as a Schedule I controlled substance — the same classification as heroin — and various politicians still reiterate many of these same myths and mistruths. Slowly but surely, the public is turning the page. 

According to Gallup, 70% of U.S. adults think “the use of marijuana should be legal.”

Keep reading